Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Acumen Pharmaceuticals, Inc. Common Stock

ABOS

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Last trade $0.2138
Day change -$0.0022 (-1.02%)
Day range $0.203 – $0.218
Volume 2,008,614
Market cap $16M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$15.91M
Price / earnings
—
Price / book
0.46×
Price / sales
—
EV / sales
—
EV / EBITDA
0.1×

Profitability

Earnings per share
-$1.44
Return on assets
-121.5%
Return on equity
-300.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.76×
Current ratio
1.89×
Quick ratio
1.89×
Cash ratio
1.18×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$87.95M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ABOS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.7M$4.75M$4.67M$4.67M$4.55M$4.63M$5.1M$5.03M
Research and development$21.11M$27.81M$16.48M$20.53M$21.97M$37.13M$25.27M$34.57M
Total operating expenses$25.81M$32.56M$21.15M$25.2M$26.51M$41.75M$30.37M$39.6M
Operating income-$25.81M-$32.56M-$21.15M-$25.2M-$26.51M-$41.75M-$30.37M-$39.6M
Interest expense-$999K-$1.09M-$1.07M-$1.09M-$1.07M-$1.05M-$1.02M-$1.04M
Income before taxes-$25.37M-$32.72M-$20.74M-$25.14M-$26.45M-$40.95M-$28.8M-$37.15M
Income taxes$0$0$0$0$0$0$0$0
Net income-$25.37M-$32.72M-$20.74M-$25.14M-$26.45M-$40.95M-$28.8M-$37.15M
Net income attributable to common shareholders-$25.37M-$32.72M-$20.74M-$25.14M-$26.45M-$40.95M-$28.8M-$37.15M
EBITDA-$25.8M-$32.55M-$21.14M-$25.19M-$26.5M-$41.73M-$30.36M-$39.58M
Basic earnings per share-$0.35-$0.45-$0.33-$0.41-$0.44-$0.68-$0.48-$0.62
Diluted earnings per share-$0.35-$0.45-$0.33-$0.41-$0.44-$0.68-$0.48-$0.62

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

Acumen Pharmaceuticals expects to report Phase II trial results for its Alzheimer's drug candidate sabirnetug in November 2026, testing whether targeting amyloid-beta oligomers slows cognitive decline. The company has $79 million in cash reserves supporting operations into early 2027, and its enhanced brain delivery platform showed a 40-fold increase in brain exposure in preclinical studies, positioning it for potential regulatory filings in mid-2027.

The Motley Fool

Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash reserves of $78.6 million expected to support operations into early 2027. The company is preparing for November 2026 topline results from its Phase 2 ALTITUDE-AD trial testing sabirnetug for early Alzheimer's disease, with 542 participants enrolled. Management expects a 30% slowing of cognitive decline on the iADRS scale as the clinical success benchmark and anticipates low double-digit ARIA-E safety rates. The company is also advancing its Enhanced Brain Delivery program toward an IND filing in mid-2027.

GlobeNewswire Inc.

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.

GlobeNewswire Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.

GlobeNewswire Inc.

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals reported Q1 2026 financial results with cash reserves of $128.4 million. The company expects topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026, and plans to file an IND for its lead EBD program candidate in mid-2027. R&D expenses decreased to $16.5 million from $25.3 million year-over-year due to reduced manufacturing and CRO costs following ALTITUDE-AD enrollment completion.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.